Pieris Pharmaceuticals, Inc. General form of registration statement for all companies including face-amount certificate companies

Statement of Changes in Stockholders' Equity (USD $)	Total	Series A Preferred Stock [Member]	Series A 1 Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Receivables from Stockholder [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]
Beginning Balance at Dec. 31, 2011	$ 2,822,229us-gaap_StockholdersEquity	$ 378,503	$ 173,896	$ 662,515	$ 53,889	$ 56,400,054	$ (170,491)	$ (973,403)	$ (53,702,734)
Beginning Balance shares at Dec. 31, 2011		324,313	132,432	462,963	59,993
Net income (loss)	(2,320,546)us-gaap_NetIncomeLoss								(2,320,546)
Foreign currency translation adjustment	(5,980)							(5,980)
Waiver of receivable from issuance of shares						(48,690)	48,690
Ending Balance at Dec. 31, 2012	495,702us-gaap_StockholdersEquity	378,503	173,896	662,515	53,889	56,351,363	(121,801)	(979,383)	(56,023,280)
Ending Balance shares at Dec. 31, 2012		324,313	132,432	462,963	59,993
Net income (loss)	66,196us-gaap_NetIncomeLoss								66,196
Foreign currency translation adjustment	23,109							23,109
Ending Balance at Dec. 31, 2013	$ 585,007us-gaap_StockholdersEquity	$ 378,503	$ 173,896	$ 662,515	$ 53,889	$ 56,351,363	$ (121,801)	$ (956,274)	$ (55,957,084)
Ending Balance shares at Dec. 31, 2013		324,313	132,432	462,963	59,993

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.